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VariabilityCMV) viral chemokine, UL146, and TNF α-like receptor UL144 genes show a high
degree of hypervariability in clinical isolates. These proteins are predicted to be immune modulators and may
contribute to the pathogenesis of HCMV infections. We analyzed the UL146 and UL144 genetic variation of 51
HCMV isolates from congenitally infected children and 13 isolates from children in childcare. There was no
statistically signiﬁcant correlation between UL146 and UL144 genotypes and HCMV disease and/or sequelae.
However, there were some groups that had a relatively large proportion of asymptomatic outcomes. These
included UL146 group 8 (7/8 asymptomatic) and UL146 group 10 (3/3 asymptomatic). UL144 group B had 11/15
(73%) asymptomatic. UL146 and UL144 genes remained stable in serial isolates from children in daycare for
intervals up to three years. These results indicate that most UL146 and UL144 genotypes do not predict clinical
sequelae following congenital HCMV infections.
© 2008 Elsevier Inc. All rights reserved.Introduction
Human cytomegalovirus (HCMV) is a ubiquitous β-herpesvirus,
congenitally infecting about 1% of all newborns in the United States
(Stagno et al., 1982). 0.1% of these infected infants display clinical
manifestations at birth such as microcephaly, hepatosplenomegaly,
jaundice, petechiae, or chorioretinitis (Pass et al., 2006). Of those with
clinical symptoms at birth, most develop long-term neurodevelop-
mental sequelae. 100% of these children will have lower intelligence/
developmental quotient (IQ/DQ), 65% will have some hearing loss, and
53% will be diagnosed with mental retardation (Noyola et al., 2001;
Williamson et al., 1982). Even those newborns that are asymptomatic
at birth can develop clinical outcomes of hearing loss and learning
disabilities, which may not manifest themselves until they are older
(Pass, 2005). Due to this lasting morbidity, the Institute of Medicine
recently ranked the development of a CMV vaccine as a top priority
based of the overall cost and human suffering (Arvin et al., 2004). Tol rights reserved.develop an adequate and effective vaccine or drug, a thorough
understanding of the viral proteins that cause clinical disease are
necessary.
The outcomes of congenital HCMV infections are determined by a
variety of factors. Timing of infection, cell types infected at the
placental interface (McDonagh et al., 2006; McDonagh et al., 2004),
andmaternal antibody titers (Fowler et al.,1992) are among the factors
that may affect clinical outcomes. Several investigators have specu-
lated that HCMV genes are important in the pathogenesis of human
infections. HCMV possesses genes that are predicted to be involved in
immune evasion that could function to increase viral survival or spread
(Akter et al., 2003; Bentz et al., 2006; Mocarski, 2002; Sutherland,
Chalupny, and Cosman, 2001; Tomasec et al., 2000; Tomazin et al.,
1999; Waldhoer et al., 2002; Wang, Bresnahan, and Shenk, 2004;
Wyrwicz and Rychlewski, 2007). There are a large number of open
reading frames (~62) in HCMV that are “non essential” for virus
replication in vitro but may have a role in immune evasion in vivo. The
15 kb, UL/b′ genomic region of the virulent Toledo strain contains at
least 19 open reading frames (ORFs) which are not present in
laboratory-adapted strains such as the AD169 strain (Cha et al., 1996;
87J. Heo et al. / Virology 378 (2008) 86–96Prichard et al., 2001). The products of two of these ORFs: vCXCL-1 (also
called pUL146 and vCXC-1) from the UL146 gene and vCXCL-2 (also
called pUL147 and vCXC-2) from the UL147 gene have limited
homology to CXC chemokines (Cha et al., 1996). UL147 has only limited
variability in the coding region for the mature protein. Variability is
limited to the signal sequence portion of UL147. The vCXCL-1
chemokine from the Toledo strain, vCXCL-1Tol, induces neutrophil
chemotaxis and calcium mobilization (Penfold et al., 1999). Recently,
numerous HCMV genomes from clinical isolates have been sequenced
(Dolan et al., 2004) and have shown that the UL146 gene, along with
the UL139 (Qi et al., 2006) and UL144 genes, are some of the most
variable genes in the entire HCMV genome. The evolutionary reasons
for this variability are unknown.
One hint of the role that vCXCL-1 plays during in vivo infection
comes from early vaccine trials (Plotkin et al., 1989). During this study,
two strains, Toledo and Towne, were inoculated into naïve adult
volunteers and the degree of febrile illness measured. The outcome ofTable 1
Clinical isolates of congenital CMV infection
* UL144 clades of TX11, TX12, and TX05 were identiﬁed by Bale et al. (2001).this study showed that the Toledo strain generated febrile illness at a
tenfold lower dose than Towne, implying that Toledo is more virulent
than Towne. When these genomes were sequenced, the UL146 genes
were shown to be signiﬁcantly different. This example is commonly
used as proof of the role that vCXCL-1 plays in HCMV pathogenesis.
Because of the variability in UL146, it has been suggested that
vCXCL-1 proteins correlate with differences in long-term outcomes
following congenital infections or during reactivation in immune
compromised patients. Several groups have analyzed the association
between disease outcomes and of UL146 variability (Arav-Boger et al.,
2006b; Arav-Boger, Zong, and Foster, 2005; Hassan-Walker et al.,
2004; Lurain et al., 2006; Stanton et al., 2005). These clinical
specimens were isolated from immunocompromised adults or
congenitally infected newborns within ﬁrst three weeks of life. In
adult renal transplant patients there was no correlation with clinical
outcomes and UL146 genotypes (Hassan-Walker et al., 2004). In the
congenital studies, the analysis did not take into consideration long-
88 J. Heo et al. / Virology 378 (2008) 86–96term sequelae. The analysis of congenitally infected infants was based
solely on symptoms at birth (Arav-Boger et al., 2006b, 2005; Hassan-
Walker et al., 2004; Lurain et al., 2006; Stanton et al., 2005). This could
lead to an underestimate of the number of asymptomatic children as
HCMV infections leading to learning disabilities or mental retardation
may not become apparent until months or years after birth (Pass,
2005).
Another member of UL/b′ region, UL144, is also variable and a
potential virulence factor (Benedict et al., 1999). This protein has
limited similarity to the herpes simplex virus entry mediator (HVEM),
a member of the tumor necrosis factor receptor superfamily (TNFRSF)Fig. 1. Amino acid alignments of the mature forms of vCXCL-1s from clinical isolates. vCXCL-
isolates are indicated in bold. The vCXCL-1 sequences from reference strains Toledo, Towne
(GenBank accession numbers AY681092, AY681095, DQ115733, DQ115734, DQ115735, DQ1
AY446868, AY446890, AY446894, and AY446889, respectively) plus strain [F] from Prichard e
binding and activation, are indicated at the top. Residues that are 100% conserved are shaded
grey. Consensus sequences with 100%, 90%, and 80% conservations are shown at the bottom(Benedict et al., 1999). The UL144 protein, however, does not bind any
known TNF-related ligands (Benedict et al., 1999; Lurain et al., 1999;
Poole et al., 2006). To date, only one ligand, the Ig superfamily mem-
ber B and T lymphocyte attenuator (BTLA), has been shown to bind to
the UL144 protein (Cheung et al., 2005). By binding to BTLA, UL144
could decrease the lymphocyte responses to HCMV. Recently, UL144
has been shown to activate TNFR-activated factor 6 (TRAF6) leading
to NFKB activation, a pleiotropic transcription factor (Poole et al.,
2006). NFKB activation enhances expression of the chemokine CCL22,
which attracts Th2 and regulatory T cells. Therefore, the authors spe-
culate that upregulation of CCL22 may help HCMV evade immune1 amino acid sequences from 51 clinical isolates were analyzed. 18 symptomatic clinical
, C952, C954, C956, E760, ML1, TB40/E, FS, AL, 6397, KM, RK, Davis, NT, Merlin, and KSG
15754, AY446880, AY446866, AY446877, AY446887, AY446870, AY446893, AY446885,
t al. (2001) are boxed. The ELRmotif and N-loop region, which are important in receptor
black and residues that are conserved in greater than 80% of the sequences are shaded in
.
89J. Heo et al. / Virology 378 (2008) 86–96surveillance, resulting in increased viral spread. Data regarding the
association between UL144 genotypes and the outcomes of congenital
infection is conﬂicting. While Arav-Boger et al reported an association
(Arav-Boger et al., 2006a, 2002), others have not (Bale et al., 2001;
Lurain et al., 1999; Mao et al., 2007; Tanaka, Numazaki, and Tsutsumi,
2005; Yan et al., 2008).
Our study addresses whether there is an association between
speciﬁc UL146, UL147, and UL144 genotypes and symptoms at birth in
congenitally infected children. Many of these children that were
asymptomatic at birth were followed for several years to ensure that
there were no long-term sequelae. In addition, serial isolates from
children who shed HCMV over long periods of time were analyzed
to examine whether UL146 hypervariability is driven via immune
pressure.
Results
vCXCL-1s from children with congenital HCMV infection can be divided
into 11 distinct clades
To understand whether speciﬁc vCXCL-1s correlate with clinical
outcomes, 51 samples were analyzed from 50 congenitally infected
children (Table 1). TX11 and TX12 were from same child. Using
primers upstream and downstream of the UL146 and UL147 genes
(Arav-Boger et al., 2005) PCR products were obtained from the 51
clinical isolates. Each sample was PCR ampliﬁed twice, TA cloned,
and two to ﬁve clones were sequenced. The accuracy rate was
greater than 99.9% between the two separate PCR reactions. For
reference sequences, we included the previously analyzed strainsFig. 2. vCXCL-1 phylogenetic analysis. The mature forms of vCXCL-1 from 51 clinical isolate
using ClustalX. 18 symptomatic clinical isolates are indicated in bold. Bootstrap numbers arToledo, Towne, C952, C954, C956, E760, ML1, TB40/E, FS, AL, 6397,
KM, RK, Davis, NT, Merlin, and KSG (Dolan et al., 2004; Lurain et al.,
2006) in addition to the F strain from Prichard et al (Prichard et al.,
2001). The UL146 ORFs encode vCXCL-1 proteins containing between
115–121 amino acids. The mature forms without the signal sequence
and the reference sequences contain between 93–98 residues that
show 4% identity (5 residues) and 5% similarity (6 residues) (Fig. 1).
All sequences were assigned to 11 distinct vCXCL-1 clades (Fig. 2).
The intravariability within each clade was less than 6%. The
designated genotypic group numbers were assigned according to
the 14 UL146 groups described by Dolan et al (Dolan et al., 2004). No
vCXCL-1 sequences were found in groups 2, 3, 4 and 5. Interestingly,
however, we assigned a new vCXCL-1 group designated group 15
(Fig. 2).
If the two most distant reference groups are removed (Merlin and
NT from Group 2 and 4, for which we did not assign any samples), the
number of 100% consensus residues doubles from 5 to 10. This
includes the CXC chemokine motif and the four cysteine residues.
This implies that these two isolates are very distant cousins of other
vCXCL-1s. This number increases to 12 when all of the reference
sequences are removed from the analysis. These conserved residues
provide the essential structure for all α-chemokines (Fernandez and
Lolis, 2002). The vCXCL-1 sequence of TX15 replaces the glutamic
acid–leucine–arginine (ELR) with asparagine–glycine–arginine
(NGR) motif, which is similar to the NRG containing chemokine
found in the ML1 strain (Dolan et al., 2004) (Fig. 1). Modiﬁcation of
the ELR motif (E → N and L → G) could have profound effects on
chemokine function as the ELR motif is necessary for chemokine
activity and receptor binding (Clark-Lewis et al., 1991; Schraufstatters with the reference sequences (shaded grey) were assembled into a phylogenetic tree
e shown. Group designations correspond to those used by Dolan et al. (2004).
90 J. Heo et al. / Virology 378 (2008) 86–96et al., 1993). To further identify possible functional differences that
are reﬂected in their sequences, we clustered the groups based on
their N-loop regions. The N-loop region, the residues between the
second cysteine and the 310-helical turn (approximately 8–10
residues), is responsible for receptor engagement and function
(Clark-Lewis et al., 1994; Fernandez and Lolis, 2002; Lowman et al.,
1996). Analysis of these sequences divides the chemokines into the
same 11 groups indicating that the N-loop region is mainly
responsible for vCXCL-1 variability (Fig. 3). There is 0% similarity
within this region between the different clades. The fact that there is
hypervariability within this region implies that these chemokines
may have different afﬁnities for the chemokine receptors and could
trigger different downstream signaling and subsequent functions.
Differences in afﬁnity, apoptosis, and integrin expression has been
noted for chimpanzee CMV vCXCL-1 compared to vCXCL-1Tol (Miller-
Kittrell et al., 2007).
The variability of vCXCL-1 does not show a deﬁnitive correlation
between speciﬁc vCXCL-1 sequences and HCMV sequelae. Overall,
there was not a statistically signiﬁcant association between vCXCL-1
clades and symptoms at birth (p=0.37). However, examination of
individual clades did reveal three clades with an unusually high
proportion of asymptomatic children. These were group 8 with 7 of 8
(88%) asymptomatic (95% CI: 47% to 100%), group 10with 3 of 3 (100%)
asymptomatic (95% CI: 29% to 100%) and group 12 with 5 of 6 (83%)
asymptomatic (95% CI: 36% to 100%).
One isolate, 300016, is assigned to two vCXCL-1 groups (group 1
and 13) (Fig. 2). After resequencing and analyzing 10 clones, these
assignments still held. This indicates this child was infected with two
different HCMV isolates as has been seen in both congenital infections
and immune compromised patients (Arav-Boger et al., 2006b; Lurain
et al.; 2006 Dolan et al., 2004).Fig. 3. Phylogenetic analysis for the N-loop region of vCXCL-1. The N-loop regions of vCXCL-1
ClustalX.18 symptomatic clinical isolates are indicated in bold. Bootstrap numbers are shown.vCXCL-2 fromchildrenwith congenitalHCMV infection has limited variability
The UL147 ORF from the same set of clinical isolates encodes
vCXCL-2 proteins comprised of 157–167 amino acids (Fig. 4). In
contrast to the vCXCL-1 protein the mature form of the vCXCL-2 from
the clinical isolates were all identical lengths (119aa). Themature form
of vCXCL-2 shows 87% identity (103 residues) and with an additional
11% similarity (13 residues) overall. Because of the limited variability
of UL147 sequences from clinical isolates, the alignment of the mature
vCXCL-2 proteins falls into a single group. As previously published, the
only signiﬁcant variability within vCXCL-2 occurs in the signal
sequence (Arav-Boger, Zong, and Foster, 2005), which is cleaved
during protein maturation.
UL144 sequences fall into three genotypes
UL144 is a member of the TNF receptor family (Benedict et al.,
1999). Arav-Boger et al showed a direct link between speciﬁc UL144
genotypes and clinical outcomes (Arav-Boger et al., 2006a, 2002)
while others have not (Bale et al., 2001; Lurain et al., 1999; Mao et al.,
2007; Picone et al., 2005; Tanaka et al., 2005; Yan et al., 2008). In order
to establish whether speciﬁc clades of UL144 are associated with
clinical outcomes, 44 UL144 sequences from the 51 clinical isolates
were ampliﬁed and sequenced. We included the sequences of
genotypes A, B, C, AB, and AC (GenBank accession numbers
AF498086–AF498090) as reference sequences. The UL144 ORF
encodes a protein of 175–176 amino acids. The UL144 mature form
without the signal sequence is between 146–157 residues in length
with 60% identity (95 residues) with an additional 27 similar residues
(Fig. 5). These UL144 amino acid sequences separate the isolates into
ﬁve major genotypic groups (A, B, C, and subgroup AB and AC) (Fig. 6).from 51 clinical isolates with the reference sequences (in grey box) were analyzed using
Groupdesignations correspond to those of themature forms ofUL146 amino acid (Fig. 2).
Fig. 4. Alignment of the mature forms of vCXCL-2. vCXCL-2 sequences from 51 clinical isolates were analyzed. 18 symptomatic clinical isolates are indicated in bold. The reference
strains Toledo and Towne (GenBank accession numbers AY681092 and AY681095, respectively) were included and are boxed. Residues that are 100% conserved are shaded black and
residues conserved in 80% to 99% of the sequences are shaded grey. The consensus residues with 80% conservation is shown at the bottom.
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groupings based on UL144 sequences (Arav-Boger et al., 2002; Lurain
et al., 1999). We used the UL144 classiﬁcation of Arav-Boger et al for
this study. Bale et al showed UL144 variability from 16 congenitally
HCMV infected children (Bale et al., 2001). They found that clinical
isolates TX11 and TX12, which were obtained from same child,
showed different UL144 group designations, group 3 (or B) and group
1 (or A). Once again this indicates a child with multiple HCMV
infections. Interestingly, our results mapped the UL146 genotypes of
these two isolates to the same clade (group 11), which were conﬁrmed
by two separate PCR ampliﬁcations and sequencing of ﬁve clones each
(Fig. 2). This implies divergence within UL144 and that the two strains
could have evolved under different environmental pressures.
The UL144 protein consists of two cysteine-rich domains (CRD),
one transmembrane domain (tm), and one cytoplasmic domain (cyto).
Unlike the TNFR, UL144 lacks an additional CRD3 region which may
explain absence of binding to TNF-like ligands (Benedict et al., 1999).
The alignments show that UL144 CRD1, which is comprised of 34
residues, shows 50% identity (17 residues) and this percentage
increases to 71% when similar residues are included. The CRD2 is
slightly more conserved. Of the 36–37 residues, there is 57% identity
(21 residues) and 81% similarity. BTLA binds to the CRD1 of HVEM,
which is homologous to UL144 CRD1 (Cheung et al., 2005). As
observed in previous studies there is a high level of conservation inthe transmembrane and cytoplasmic domains of UL144 between
the different isolates (Arav-Boger et al., 2002; Lurain et al., 1999). The
variability in the CRD regions has been used to infer that the
interaction between UL144 and BTLA could differ between the
different genotypes, leading to differential virus survival and/or
clinical outcomes.
Using our clinical samples from congenitally infected children, we
show that the UL144 genotype does not correlate with HCMV
sequelae. Using Fisher's exact test, therewas no statistically signiﬁcant
association between UL144 genotype and symptoms (p-value=0.45).
Group B in our sample did have 18 of 23 (78%) asymptomatic (95%
CI: 45% to 92%) while groups A and C had lower percentages
of asymptomatic newborns (Group A=69% (9/13) and Group C=40%
(2/5)). This data indicates that there is no direct correlation between
UL144 genotypes and symptoms at birth, although the trend of more
asymptomatic children in group B is similar to the ﬁndings of Arav-
Boger et al. (2002, 2006a).
UL146 genes under immune selection pressure do not mutate
One explanation for the variability in the UL146 gene is that UL146
evolves to avoid the immune response. To address whether the UL146
gene accumulates mutations while under immune selection pressure,
we studied serial HCMV isolates from children who shed HCMV over
Fig. 5. UL144 contains highly conserved domains. UL144 amino acid sequences from 44 clinical isolates were analyzed. 13 symptomatic clinical isolates are indicated in bold.
Representative sequences from genotype groupings A, B, C, AB, and AC (GenBank accession numbers AF498086–AF498090) were included as reference sequences and are boxed.
Residues that are 100% conserved are shaded black and residues that are greater than 80% conserved are shaded grey. Consensus sequence with 80% conservation across all isolates
are shown at the bottom. The cysteine-rich domains (CRD), the transmembrane region (tm), and cytoplasmic tail (cyto) are indicated at the top.
92 J. Heo et al. / Virology 378 (2008) 86–96many years (Chen et al., 2004). We cloned and sequenced the UL146
ORF from 13 serial isolates from six children from daycare centers in
Virginia (Table 2). For up to three years, there was no change in vCXCL-
1 (Fig. 7). However, multiple UL146 sequences were identiﬁed from
sequential isolates from the same individual. Isolates 30135 and 31099
were assigned to group 9 and 8, and isolates 23914 and 24864 were
assigned to group 8 and 9, respectively. In order to conﬁrm that these
isolates resulted from multiple infections, we sequenced the UL144
gene from these same isolates. The UL144 sequences from isolates
23914 and 24864 were assigned to group A and B. This data indicates
that these children were infected with two different viruses and that
the UL146 gene did not accumulated multiple mutations leading to
the assignment to a new clade.
Discussion
There have been several studies addressing the effect of UL146
variation on HCMV pathogenesis in immune compromised patients
(Arav-Boger et al., 2005; Dolan et al., 2004; Hassan-Walker et al.,
2004; Lurain et al., 2006; Stanton et al., 2005). The UL146 ORF is one of
the most variable genes in the HCMV genomes following analysis of
isolates from AIDS or organ transplant patients (Dolan et al., 2004;
Hassan-Walker et al., 2004; Prichard et al., 2001). These studies lead to
the classiﬁcation of UL146 sequences into 14 groups. This variability,
its role as a chemokine and its absence from lab attenuated strains,
lead to the hypothesis that this gene could encode a virulence factor.
Dolan et al, Hassan-Walker et al, and Arav-Boger et al investigated
the link between speciﬁc UL146 clades and symptomatic/asympto-
matic congenital infections (Arav-Boger et al., 2006b; Dolan et al.,2004; Hassan-Walker et al., 2004). Arav-Boger et al showed that from
21 clinical isolates no speciﬁc UL146 genotype was associated with
disease outcome (Arav-Boger et al., 2006b). Hassan-Walker et al and
Dolan et al showed 4 and 14 genetic groups, respectively. However,
due to the small sample size (14 and 7, respectively) they could not
draw a direct link between genotypes and symptoms (Dolan et al.,
2004; Hassan-Walker et al., 2004).
Even though our study includes a relatively large sample size, we
are unable to reach statistically signiﬁcant conclusions about speciﬁc
UL146 clades and symptomatic outcomes. Our results demonstrate
that out of the 15 groups, 11 of the clades did not exhibit a deﬁnitive
association between UL146 genotypes and symptoms. Group 10 con-
tained only asymptomatic children but had a sample size of 3. In group
8 only 1 out of 8 were symptomatic. From this data we can conclude
that most of the UL146 genotypes do not correlate with symptomatic
births and two of these (Group 8 and Group 10) groups point towards
asymptomatic outcomes but a statistically signiﬁcant conclusion is
limited because of sample size.
The other gene located within the ULb′ region, which has
homology to the TNF receptor and is variable is UL144. Our UL144
data in this study shows a lack of correlation between symptoms
and UL144 clades supports the ﬁndings of several other studies (Bale
et al., 2001; Lurain et al., 1999; Mao et al., 2007; Picone et al., 2005;
Tanaka et al., 2005; Yan et al., 2008). Only Arav-Boger concluded
that UL144 is predictive of congenital infection outcomes (Arav-Boger
et al., 2006a, 2002). The major differences between these studies are
the sample size and the source of the isolates. Arav-Boger et al sug-
gested that groups A and C are associated with more serious out-
comes upon analysis of 23 congenitally infected isolates comprised of
Table 2
Serial isolates from VCU day care
Fig. 6. UL144 sequences fall into 5 groups. The mature forms of UL144 amino acid sequences from 44 clinical isolates were analyzed by the ClustalX. 13 symptomatic clinical isolates
are indicated in bold. Reference sequences are illustrated with grey boxes. Group designations correspond to those of Arav-Boger et al. (2002).
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with both asymptomatic (10 out of 10) and symptomatic (6 out of 13)
children and the A and C genotypes were only found in the
symptomatic children (Arav-Boger et al., 2002). From this, they
concluded that the A andC genotypes are associatedwith symptomatic
outcomes. This group also showed a possible relationship between C
genotype and symptomatic diseases in newborns in a study in Italy.
They showed a statistically signiﬁcant association between the C
genotype and termination of pregnancy, while the B genotype did not
(Arav-Boger et al., 2006a). This study did suffer from enrollment biases
as women were enrolled based on a higher risk for congenital CMV
infections. In contrast, Bale et al examined 51 HCMV isolates from 44
patients containing 16 congenitally infected children to conclude that
UL144 genotype does not correlate with symptoms at birth (Bale et al.,
2001). Others have corroborated the Bale study. Mao et al analyzed
70 isolates from Chinese infants where 58 were from symptomatic
children but only ﬁve infants were determined to have acquired CMV
from congenital infections (Mao et al., 2007). An even larger Japanese
study assessed the UL144 sequences from 74 Japanese HCMV isolates
where 10 samples were from congenitally infected newborns (Tanaka
et al., 2005). AnalyzingHCMVcongenitally infected fetuses, Picone et al
concluded that there was no correlation between severity of infection
and UL144 genotype (Picone et al., 2005). All of these studies divided
theUL144 genotypes into threemajor groups: 1, 2, and 3 (or A, C, and B,
respectively) and did not ﬁnd a statistically signiﬁcant relationship
between these genetic groups and speciﬁc clinical symptoms at birth.
In our study, 23 of 44 samples had the B UL144 genotype. Of these, 5 of
23 infants were symptomatic while 18were asymptomatic. In contrast
to the study of Arav-Boger, we observed that both A and C clades
contain both asymptomatic and symptomatic children (Fig. 6). There-
fore, our analysis of theUL144 sequences agreeswith previous ﬁndings
of Bale et al.Because of its high variability, UL146 sequences can be used as an
indicator of multiple HCMV infections. Multiple HCMV infections
could be due to either incomplete protection after HCMV infection or
coinfection simultaneously with different strains of HCMV. Multiple
infections have been found in both congenitally infected isolates
(Arav-Boger et al., 2006b), renal transplant patients (Lurain et al.,
2006), bonemarrow transplant patients (Lurain et al., 2006), and AIDS
patients (Dolan et al., 2004). In immunocompetent children, Bale et al
studied 11 serial isolates from ﬁve children for up to 2.5 years and
found multiple sequences (Bale et al., 2001). Based on the genetic
stability of UL146 sequence, multiple sequences were not due to
random mutations. Therefore the multiple sequences were due to
coinfectionwith another strain of HCMV.We have also foundmultiple
sequences from children in daycare (Fig. 7A) indicating that coinfec-
tions with multiple strains of HCMV are possible.
Fig. 7. vCXCL-1 does not mutate in long-term shedders. vCXCL-1 from 13 serial isolates from 6 children for up to 3 years were analyzed. A) The alignments shown are from individual
children over a span of one to three years. Residues that are 100% conserved are shaded black and grey regions residues indicate conservative substitutions. B) ClustalX was used for
phylogenetic analysis of the different isolates.
94 J. Heo et al. / Virology 378 (2008) 86–96Since UL146 and UL144 genes are variable, many studies have
addressed the stability of UL146 or UL144 genotype upon serial
isolation over many years (Arav-Boger et al., 2002; Dolan et al., 2004;
Hassan-Walker et al., 2004; Lurain et al., 2006; Stanton et al., 2005;
Tanaka et al., 2005). Lurain et al studied various organ transplant
recipients for up to 5 years with no changes in UL146 sequence
(Lurain et al., 2006). Both in vitro (Lurain et al., 2006) and in immune
compromised hosts, UL146 did not mutate over time (Hassan-Walker
et al., 2004). A possible explanation of UL146 and UL144 hypervaria-
bility could be due to immune selection pressure within the host.
Our study (Fig. 7) and Bale et al analyzed immunocompetent child-
ren shedding virus over many years. This would have allowed for
vigorous immune selection compared to the transplantation studies
where the host is immune suppressed and are often treated with
anti-CMV drugs. Immune selection could select for mutated, secreted
vCXCL-1 protein that is recognized as foreign, because it is only ~20–
30% homologous to host chemokines. Interestingly, Lurain et al
showed no variation in UL146 sequences even when different
patients received organs from the same donor. These organs con-
tained the same strain of HCMV from the donor but were
transplanted into different hosts, which could mount different
immune responses (Lurain et al., 2006). This shows the stability of
UL146 over time and in the different immunological settings from
different individuals.
Most immune competent individuals shed HCMV for about 9–
12 months after acquisition. In contrast, primary CMV infection of
neonates and infants results in continuous viral shedding into the
urine and saliva for several years (Adler, 1992; Stagno and Cloud,1994;
Tu et al., 2004). Our data are unique in that our samples were isolated
from healthy children (i.e. not immunocompromised). If immune
selection drives UL146 variation, our analysis should identify it. Our
data from healthy children also agrees with the studies from immu-nocompromised patients. We found 2 cases of coinfection, which fell
into group 8 and 9, but no sequence changes were detected during
two years, indicating that virus maintains its genetic integrity under
healthy immune defense. If mutations are not occurring in this time
frame, how and why are these genes so variable? One possibility is
that changes in the genes accumulated during HCMVs' co-evolution
with humans. The gradual changes in UL146 and UL144 provide
an evolutionary advantage, which only becomes dominant over
millennia.
In conclusion, this study shows that speciﬁc UL146 and UL144
genotypes do not correlate with the sequelae of congenital infection.
We also show that some children in daycare are infectedwithmultiple
strains of HCMV and that their HCMV UL146 genotypes do not change
over several years.
Materials and methods
Clinical subjects and specimens
HCMV isolates from symptomatic and asymptomatic congenitally
infected children for phylogenetic analysis were obtained from two
geographically distant locations at four facilities: 40 HCMV isolates
from Iowa (four hospitals in Iowa City and Cedar Rapids, IA) and 11
isolates from Texas. Six isolates from the Texas clinic were from a
previous study (Bale et al., 2001). Together, there are 18 symptomatic
(K.P., Sk, A.B., P.L., Ca, 100546,101027, 102124,102226,102410, 300584,
TX03, TX11, TX12, TX20, TX21, TX24, and TX30) and 33 asymptomatic
children (100427, 100457, 100691, 100738, 100751, 101142, 101329,
101430, 101465, 102429, 200164, 200550, 201334, 201370, 300016,
300482, 300521, 300667, 301217, 301699, 302281, 400191, 400328,
400340, 400600, 400818, 400865, 401058, 401361, TX05, TX15, TX25,
and TX32) (Table 1).
95J. Heo et al. / Virology 378 (2008) 86–96For the evolution of UL146 over time, 13 serial viral isolates from
six children attending six day care centers in Virginia were grown in
vitro and sequenced (Table 2).
DNA isolation
DNA was isolated from the Iowa and Texas clinical isolates as
previously described (Bale et al., 2001). HCMV infected MRC-5 cells
from the VCU study were maintained until 70 to 80% cytopathic effect
(CPE) was attained. Cold Tris/EDTA buffer (0.5 ml) with 10% SDS
(50ml) and proteinase K (100mg/ml)was added to the cell pellets and
incubated for 1 h at 65 °C. Viral DNA was extracted using phenol/
chloroform and precipitated with ethanol. The DNA pellets were
washed with 70% and dried. DNA concentration was determined
spectrophotometrically (A260/A280).
PCR ampliﬁcation
The primers for the UL146 and UL147 ORFs were designed for
conserved regions that ﬂank each of the ORFs. The primers 5′-GTCA-
TGGACGCAGTTTTG-3′ (forward) and 5′-GAACGATCTCGTCCGGTTC-3′
(reverse) were identical to those used in Arav-Boger et al (2005).
The size of the PCR product is 1.2-kb. For the UL144 ORF, the primers
5′-CGTATTACAAACCGCGGAGAGGAT-3′ (forward) and 5′-CTCAGA-
CACGGTTCCGTAAAGTG-3′ (reverse), which are located upstream or
downstream of UL144 ORF, generate a 740-bp product. The PCR
conditions for UL146 and UL147ORFswere 95 °C for 2min, followed by
40 cycles of 95 °C for 30 s, 55 °C for 30 s, 72 °C for 2 min. The reaction
was extended at 72 °C for 10 min. The UL144 PCR conditions were
similar except the extension time was reduced to 1 min.
DNA sequencing
The amplicons were cloned into the pGEM-T Easy vector using the
pGEM-T Easy kit (Promega) according to the manufacturer's instruc-
tions. At least three colonies were picked and sequenced in both
directions using universal primers (SP6 and T7). For the serial isolates
from VCU, if differences were identiﬁed in the UL146 ORF, the entire
PCR reaction was repeated to ensure that any differences were due to
differences in viral DNA and not due to a PCR ampliﬁcation error. All
conﬁrmed sequences were submitted to GenBank (Accession num-
bers: UL146: EU514891–EU514955; UL147: EU514794–EU514845;
UL144: EU514846–EU514890).
Phylogenetic analysis
The sequencedORFswere converted to amino acid using VectorNTI
9 (InforMax). The predicted mature forms of vCXCL-1 and vCXCL-2
were generated with Signal P (www.cbs.dtu.dk/services/SignalP).
Alignments of the mature forms of vCXCL-1, vCXCL-2, and UL144
proteins were aligned using the ClustalX 1.83. Neighbor-joining
phylogenetic trees were generated using ClustalX 1.83 with 1000
bootstrap trials. The generated phylogenetic tree was viewed by
TreeView (Win32) 1.6.6.
Statistical analysis
Associations between genotype and whether any symptoms were
observed were analyzed using Fisher's exact test. For each individual
clade, we also calculated a 95% conﬁdence interval for the proportion of
asymptomatic individuals. All analyses were performed using SAS v9.1.
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